Markets · Explainer

Merck at 134 Times Earnings: The Dow’s Priciest Five

The selloff left Walmart at 48 times profit and Apple near 39. Merck’s much higher multiple starts with the cost of buying its next medicines.

A researcher holds a vial while an accountant studies a thin earnings receipt and customers queue at a retailer.
A researcher holds a vial while an accountant studies a thin earnings receipt and customers queue at a retailer.Kunkafa AI market forecasts and analysis tool

Kunkafa News · Published · 4 min read

Kareem FaridBy Discuss with the author on X

Here is a visual story in summary

1 / 6
Merck at 134 Times Earnings: The Dow’s Priciest Five Merck fell 3.6% on November 19. At the close, its $132.81 share price bought just $0.99 of trailing annual profit. · Kunkafa · Nasdaq and company filings · Nov 19, 2026
Merck at 134 Times Earnings: The Dow’s Priciest Five Merck fell 3.6% on November 19. At the close, its $132.81 share price bought just $0.99 of trailing annual profit. · Kunkafa · Nasdaq and company filings · Nov 19, 2026Kunkafa AI market forecasts and analysis tool
Five stocks above 32 times earnings Merck 134.2× · Walmart 48.1× · Johnson & Johnson 40.6× · Apple 38.9× · Visa 32.7×. The median across all 30 Dow stocks was 21.2×. · Kunkafa · Nasdaq and company filings · Nov 19, 2026
Five stocks above 32 times earnings Merck 134.2× · Walmart 48.1× · Johnson & Johnson 40.6× · Apple 38.9× · Visa 32.7×. The median across all 30 Dow stocks was 21.2×. · Kunkafa · Nasdaq and company filings · Nov 19, 2026Kunkafa AI market forecasts and analysis tool
What made Merck’s profit so small? Merck expensed $5.93 per share for two drug acquisitions. Add back just those charges and the multiple falls to 19.2×. Can the medicines earn back their cost? · Kunkafa · Nasdaq and company filings · Nov 19, 2026
What made Merck’s profit so small? Merck expensed $5.93 per share for two drug acquisitions. Add back just those charges and the multiple falls to 19.2×. Can the medicines earn back their cost? · Kunkafa · Nasdaq and company filings · Nov 19, 2026Kunkafa AI market forecasts and analysis tool
What would justify Walmart at 48×? Online sales grew 17% last quarter. At an unchanged share price, annual earnings would need to rise about 20% to bring the multiple down to 40×. · Kunkafa · Nasdaq and company filings · Nov 19, 2026
What would justify Walmart at 48×? Online sales grew 17% last quarter. At an unchanged share price, annual earnings would need to rise about 20% to bring the multiple down to 40×. · Kunkafa · Nasdaq and company filings · Nov 19, 2026Kunkafa AI market forecasts and analysis tool
A legal bill changed the picture at J&J A proposed talc settlement and two drug-development deals weighed on profit. J&J reported $0.09 per share for the quarter. Adjusted earnings were $2.59. · Kunkafa · Nasdaq and company filings · Nov 19, 2026
A legal bill changed the picture at J&J A proposed talc settlement and two drug-development deals weighed on profit. J&J reported $0.09 per share for the quarter. Adjusted earnings were $2.59. · Kunkafa · Nasdaq and company filings · Nov 19, 2026Kunkafa AI market forecasts and analysis tool
Even growing earnings can carry a premium Apple’s annual earnings rose from $7.46 to $8.98 a share. Its multiple still stood at 38.9×. Visa ranked fifth at 32.7×. Which premium can future profits sustain? · Kunkafa · Nasdaq and company filings · Nov 19, 2026
Even growing earnings can carry a premium Apple’s annual earnings rose from $7.46 to $8.98 a share. Its multiple still stood at 38.9×. Visa ranked fifth at 32.7×. Which premium can future profits sustain? · Kunkafa · Nasdaq and company filings · Nov 19, 2026Kunkafa AI market forecasts and analysis tool

Merck lost 3.6% on Thursday and still finished as the most expensive stock in the Dow Jones Industrial Average by trailing earnings. At $132.81 a share, buyers paid $134 for each dollar of reported annual profit. Two drug acquisitions explain much of that startling price tag. [2] [4] [5]

Kunkafa ranked all 30 Dow companies at the November 19 close. Walmart, Johnson & Johnson, Apple and Visa followed Merck. The middle stock multiple was 21.2 times earnings. Even the fifth-ranked company traded above 32 times. [1]

The five highest Dow P/Es at the close

CompanyClose ($)Day (%)Trailing diluted EPS ($)P/E (×)
Merck (MRK)132.81-3.610.99134.2
Walmart (WMT)126.04-1.042.6248.1
Johnson & Johnson (JNJ)267.14-2.046.5840.6
Apple (AAPL)349.21-0.928.9838.9
Visa (V)402.25-3.1212.3232.7

Kunkafa calculations from Nasdaq closing prices and issuer filings available by November 19, 2026.

What happened to Merck’s earnings?

Merck earned $7.28 per diluted share in 2025. Replace the first nine months of that year ($6.08 of profit) with the same months of 2026 (a $0.21 loss) and just $0.99 remains. Merck expensed $3.62 per share for acquiring Cidara and $2.31 for Terns. Adding back just those two charges would lift earnings to $6.92 and bring the multiple to 19.2. That illustration leaves a real investment question: can those drug candidates earn back their cost? [3] [4] [5]

Kunkafa | Two deal charges lift Merck’s trailing P/E from an illustrative 19.2× to 134.2× on November 19, 2026
0×50×100×150×Merck, reportedMerck, adding back two chargesDow median

Kunkafa calculations using the November 19 Nasdaq close and Merck filings. The second bar adds $5.93 to reported EPS as a sensitivity test.

Johnson & Johnson likewise reported just $0.09 a share in the third quarter. It cited a charge for a proposed talc litigation resolution alongside two drug-development deals. Adjusted EPS was $2.59. A settlement can cost shareholders real money even if it occurs only once. [7]

The premium that growth has to earn

Walmart’s sales grew 5.2% and global online sales rose 17% in its latest quarter. At 48.1 times trailing profit, a buyer paid $48 for each dollar the retailer earned. If the multiple dropped to 40 with the share price unchanged, earnings would need to rise about 20% to bridge the gap. Apple’s annual diluted EPS, for comparison, grew from $7.46 to $8.98. Even after that growth, buyers still paid 38.9 times earnings. [6] [8]

How we counted

We divided each Nasdaq closing quote by trailing diluted GAAP earnings per share. For an interim report, we used the latest fiscal year plus current year-to-date EPS minus the comparable prior-year figure, on a common share basis. We used information public by the close, including Walmart’s release that morning. The screen measures the price of reported profits across Dow constituents. A fair-value estimate would also require assumptions about future profits and risk. [1] [6] [9]

Brian Feroldi questioned Walmart’s valuation at $126. Long Equity explained why the investor holds both Visa and Mastercard. Brian Feroldi · Long Equity

Perspectives on blue-chip valuations

1 / 2
Brian Feroldi questions Walmart’s valuation at $126.
Brian Feroldi (@BrianFeroldi) · 2026-11-20 13:00 UTC · Excerpt: “Average business, bad valuation.”Kunkafa AI market forecasts and analysis tool
Long Equity compares the economics of Visa and Mastercard.
Long Equity (@long_equity) · 2026-11-18 17:48 UTC · Excerpt: “Many quality investors, including myself, invest in both.”Kunkafa AI market forecasts and analysis tool

Kunkafa forecasts

Dow Jones 30

How far it could move, which way, by when, and how confident Kunkafa is.

Check the latest forecasts

More in Markets

From the Blog

All articles